started · updated
Sjögren disease research highlights cardiovascular risks and new drug efficacy
New clinical research presented at the American College of Rheumatology annual meeting provides significant insights into Sjögren disease, a chronic autoimmune disorder that affects moisture-producing glands and internal organs.
A twenty-five year population-level analysis of United States decedents from 1999 through 2024 revealed disparities in cardiovascular mortality among those with Sjögren syndrome. The study suggests that chronic inflammation and metabolic factors increase vascular risks, necessitating targeted preventive care and long-term patient surveillance.
In therapeutic developments, Novartis reported positive long-term data for ianalumab, an investigational monoclonal antibody. Clinical trial participants receiving monthly doses showed continued improvements in disease activity through week 108. Ianalumab works by targeting B-cells to alter the underlying immunological drivers of the disease.
Additionally, a multicenter randomized controlled trial evaluated the efficacy of baricitinib, an oral Janus kinase inhibitor, in treating active Sjögren disease manifestations. Regulatory reviews for ianalumab are currently underway in several countries, with a decision from the U.S. Food and Drug Administration expected by the end of the year.
Entities
American College of Rheumatology · Food and Drug Administration · Novartis · Sjögren disease